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Summary
An experiment (Exp. 1) was
conducted to determine the effect of
Excede® at arrival or at revaccination
on morbidity, mortality, and gain in
both feedlot and pasture receiving
systems. A second experiment (Exp.
2) was conducted to determine the
effect of feedlot and pasture receiving
systems on animal health. In Exp. 1, no
treatment differences were observed for
initial or final BW, or ADG. In Exp. 1,
initial BW, treatment, receiving system
(pasture or feedlot); and buyer of cattle
explained the cumulative incidence of
bovine respiratory disease (BRD). The
incidence of BRD in this study was
4.7%, 11.0%, and 13.8% for arrival,
control, and revaccination treatments
respectively. The arrival medication
effectively reduced BRD incidence. BRD
was less (P= 0.02) for pasture receiving
than feedlot receiving, averaging 7.4%
and 11.0% respectively. In Exp. 2 BRD
was less for pasture receiving than
feedlot receiving with 23% and 53%
treated for BRD respectively.
Introduction
As a general trend, the percentage
of feedlot cattle fed as “calf-feds”
relative to yearlings has increased
in recent years. The increased
trend of calf feeding can be a
health management challenge for
many feedlots. Administration of
appropriate antibiotics to control
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BRD in cattle that are at high risk of
developing BRD may be an important
management option for producers.
Often feedlots observe their greatest
health challenges 10 to 14 days after
receiving.
In addition, calves transitioning
from a pasture based ranch system
to a feedlot can experience multiple
stressors that weaken immune
function. Receiving calves with a
system like their previous ranch
environment should reduce calf
receiving stress. Therefore, receiving
calves with a pasture based system
has the potential to be a less stressful
system than feedlot pen receiving.
The objective of Exp. 1 was to
determine the effect of Excede® at
arrival or at revaccination (16-27 days
post arrival) on morbidity, mortality,
and gain of calves in both feedlot
and pasture receiving systems. The
objective of Exp. 2 was to determine
the effect of pasture vs. feedlot
receiving on morbidity and growth
performance of freshly weaned calves.
Procedure
Exp. 1 - Three treatments were
evaluated within a pasture receiving
system and feedlot receiving system:
1) control (no medication; CON), 2)
Excede® (Pfizer Animal Health, New
York, NY) on arrival (ARR), or 3)
Excede at revaccination (median 18
days post arrival; range 16-27 days;
REVAC). A total of 2,264 freshly
weaned steer calves received at the
University of Nebraska Agricultural
Research and Development Center
(Mead, Neb.) between Oct. 13 and
Oct. 22 were used in this experiment.
Steers were procured from three
buyers representing northern
Nebraska, central Nebraska, and
western Nebraska from a mixture
of “ranch-direct” and “sale barn”
sources. Steers were penned by

treatment group to minimize
environmental or “herd-immunity”
effects. The trial had a total of 12
replications for each treatment.
Twenty-one feedlot pens housed 20
head/pen (388 ft2/head; 420 head
total) to supply seven replications
per treatment in a feedlot receiving
system. The treatment groups were
assigned randomly to one of 21
pens. Fifteen pastures housed 123
head/ 14-acre pasture (1,844 head
total) for five reps per treatment.
The treatment groups were assigned
randomly to one of 15 pastures.
Steers housed in the feedlot received
ad libitum intake of a typical feedlot
receiving ration containing (DM
basis) 33% dry rolled corn, 33% wet
corn gluten feed, 33% alfalfa, and 1%
mineral supplement containing 135
mg/steer daily Deccox® (Alpharma
Inc., Fort Lee, NJ) and 200 mg/
steer daily Rumensin® (Elanco,
Greenfield, IN). Steers on one pasture
replication received only limited hay
supplementation and 16 oz Corid®
(Merial, Atlanta, Ga.) per 100 gallons
twice for coccidiosis prevention.
Pasture location, adequate pasture
forage, and management did not
require this replication to receive
concentrate supplementation. Steers
on all other pastures were provided
3 lb/head steer daily of wet corn
gluten feed plus mineral supplement
containing 135 mg/steer Decox and
200 mg/steer Rumensin daily and
cool-season grass. In addition, cattle
on these pastures received ad libitum
hay supplementation.
Steers were assigned to treatments
based on processing order within
buyer at arrival, with every third
animal assigned to each treatment.
Steers’ panel ID tags were notched
to identify treatment assignment.
Calves were processed at arrival
by receiving three separate tags for
individual identification including
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an electronic ID, panel tag, and metal
clip tag. Calves were weighed and
vaccinated with Bovi-Shield Gold
5®, and Somubac® (Pfizer Animal
Health). Calves also received a
weight dependant dose of Dectomax
Injectable® (Pfizer Animal Health)
anthelmintic. Any calves having
horns were dehorned and cauterized.
Bull calves (51 head) were identified
for banding upon completion of
the study. Calves were revaccinated
at 18 days (range 16-27 days) post
arrival. They received vaccinations
of Bovi-Shield Gold 5, Somubac
and Ultrachoice 7® (Pfizer Animal
Health). Individual animal BWs were
collected. All pasture calves also
received a dose of pinkeye vaccine
(Schering-Plough, Kenilworth, N.J.
Calves were individually weighed off
trial after 31 days (range 26-39 days).
All pens and pastures were
evaluated by the same pen riders
within day to provide equal
pull evaluation across antibiotic
treatments. A post treatment
interval (PTI) was not in effect for
the calves after receiving Excede as
pen riders were blind as to which
cattle had received Excede to prevent
preferential pulling of untreated
calves. Calves that were categorized
as respiratory pulls by the cattle
crew, based on individual animal
observation each day, were pulled,
symptoms assessed, and treated
with Draxxin® (Pfizer Animal
Health, New York, N.Y.). When a sick
calf was treated, panel ID tag was
notched to prevent receiving Excede
at revaccination (REVAC treatment
only). Animals were returned to home
housing units as soon as possible after
treatment. Any animals receiving
Draxxin were subject to a seven-day
PTI before any secondary medication
was administered.
Initial, revaccination, and final
BW were recorded for each animal.
Average daily gain and respiratory
disease incidence data were recorded
for each animal. In addition,
morbidity outcomes and causes were
recorded. Body weights, ADG, and
mortality data using the individual
animal as the observation were

compared using the Proc MIXED
procedure of SAS to analyze for
treatment effects. The Proc GENMOD
procedure of SAS was used to
analyze respiratory disease morbidity
outcomes. An animal was determined
to be a confirmed respiratory disease
observation for the trial if the animal
was treated for respiratory disease
by the animal health personnel or if
the animal died and was confirmed a
respiratory disease dead.
Exp. 2 – In the fall of 1997 1,172
head of freshly weaned ranch direct
and sale barn sourced calves were
received at the University of Nebraska
Research Feedlot. The calves were
randomly assigned to either feedlot
pens or the same pastures used for
Exp 1. Calves were managed similar to
Exp. 1 except none of the calves were
treated with preventative medication.
Results
Exp. 1 - No significant differences
(P>0.05) of initial BW (575 ± 10 lb),
revaccination BW (615 ± 12 lb), final
BW (633 ± 14 lb), or ADG (1.85 ±
0.21 lb/day) were observed due to
medication treatment. The number of
respiratory disease caused mortalities
did not differ (P> 0.05) among
treatments, albeit low. The number of
respiratory disease caused mortalities
was 1, 1, and 2 for ARR, CON, and
REVAC treatments respectively. The
variables of the GENMOD model that
explained the incidence of respiratory
diseases were initial BW, preventative
antibiotic treatment, receiving system
and buyer of cattle. Interactions of
these variables were not significant
(P> 0.05).
Initial BW, accounting for
medication treatment; affected
(P<0.01) animal respiratory
disease outcome with lighter calves
being more likely to be treated for
respiratory disease. Excede treatment
at arrival affected (P<0.01) animal
respiratory disease outcome. The
respiratory disease cumulative
incidence for this trial was 4.7%,
11.0%, and 13.8% for ARR, CON, and
REVAC treatments, respectively. The
ARR treatment reduced respiratory
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Table 1. Exp. 1 differences in BW of pasture
and feedlot received calves. Revac BW
= Revaccination BW.
Item
Initial BW, lb
Revac BW, lb
Final BW, lb
Trial ADG, lb

Pasture

Feedlot

585
621
627
1.26

589
635
661
2.36

disease cumulative incidence of this
trial (P<0.01) compared to CON. The
REVAC treatment did not reduce
respiratory disease cumulative
incidence.
The BW and ADG differences of
pasture and feedlot received steers are
presented in Table 1. Receiving steers
in a pasture based system compared
to a feedlot system significantly
reduced (P= 0.02) cumulative BRD
incidence from 11.0% to 7.4%.
No difference of BW change due to
preventative medication treatment is
presumably due to the short window
of study length (26 – 39 days on trial).
The ineffectiveness of the REVAC
treatment relative to the ARR can be
explained by animals experiencing
respiratory disease challenge and
individual animal treatment prior
to revaccination on days 16 – 27
(Figure 1). The shorter bars of the
ARR treatment indicate decreased
incidence of BRD relative to the
CON treatment. The ARR treatment
significantly (P<0.01) improved
animal health status by reducing BRD
incidence from initial processing to
revaccination. The decrease in CON
and REVAC BRD incidence after day
15 is due to the natural incidence cycle
of BRD and not revaccination which
occurred on average at day 18.
Exp. 2 pasture and feedlot daily
gain from arrival weight to 28 or
42 days post receiving was similar.
The percentage of calves treated for
BRD in the feedlot receiving system
was significantly greater than for the
pasture receiving system with 53%
and 23% treated within feedlot and
pasture receiving, respectively.
In conclusion, preventative
medication administered at arrival
effectively reduced the incidence
of respiratory disease by reducing
(Continued on next page)
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Treatment Incidence Density
0.016
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0.014
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Figure 1. Treatment Incidence Density. CON = no preventative medication, ARR = preventative at initial processing, and REVAC = preventative at
revaccination.

BRD during the first 15 days of
arrival. Administering preventative
medication at revaccination
(median day 18) in Exp. 1 was not
a feasible option for BRD control
due to animals experiencing BRD
prior to preventative medication
administration. The low incidence
of BRD (11% of controls) in Exp. 1
did not maximize the potential value
of preventative medication that is
possible with calves at higher risk
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of BRD. However, part of the low
incidence of BRD was due to pasture
receiving as feedlot received control
steer actual incidence of BRD was
21.4%. The calves from this study
will be followed to slaughter for lung
tissue damage analysis, feedlot ADG
calculation, and economic analysis.
The data will be published in a future
Nebraska Beef Cattle Report.
Pasture receiving effectively
improved animal health status by

reducing BRD incidence over feedlot
receiving.
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